Market Overview

Why Sutro Biopharma's Stock Is Trading Lower Today

Share:
Why Sutro Biopharma's Stock Is Trading Lower Today

Sutro Biopharma (NASDAQ: STRO) shares are trading lower on Thursday after Wells Fargo initiated coverage on the stock with an Overweight rating and an $18 price target.

Sutro Biopharma Inc is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF.

Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Sutro Biopharma shares were trading down 2.58% at $8.67 on Thursday. The stock has a 52-week high of $12.75 and a 52-week low of $6.

Latest Ratings for STRO

DateFirmActionFromTo
Jul 2020Wells FargoInitiates Coverage OnOverweight
May 2020HC Wainwright & Co.ReiteratesBuy
Jan 2020SunTrust Robinson HumphreyInitiates Coverage OnBuy

View More Analyst Ratings for STRO
View the Latest Analyst Ratings

 

Related Articles (STRO)

View Comments and Join the Discussion!

Posted-In: why it's movingPrice Target Initiation Analyst Ratings

Latest Ratings

StockFirmActionPT
ZTSGabelli & Co.Downgrades
AUPHHC Wainwright & Co.Maintains34.0
RCLCredit SuisseMaintains75.0
PINCCredit SuisseMaintains35.0
SUNCredit SuisseMaintains29.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com